- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.10. | Santen's Chinese venture seeks bankruptcy, with the parent's ¥2bn loan already fully provisioned | 1 | Tokyo Brief | ||
| 22.09. | Ligand Buys Royalty Rights In Santen's Ryjunea Eye Drug | 2 | RTTNews | ||
| 22.09. | Ligand Pharmaceuticals: Ligand Acquires Royalty and Milestone Interest in Santen's Ryjunea from Sydnexis for $23 Million | 332 | GlobeNewswire (Europe) | Ryjunea is the first and only pharmacologic treatment approved by the European Commission and UK MHRA to slow myopia progression in pediatric patients Ligand will receive a tiered low-double-digit... ► Artikel lesen | |
| 06.08. | Santen Pharmaceutical Co., Ltd. Q1 Income Rises | 1 | RTTNews | ||
| SANTEN PHARMACEUTICAL CO LTD ADR Aktie jetzt für 0€ handeln | |||||
| 05.08. | Santen Pharmaceutical Co., Ltd.: Santen Joins Inaugural Global Summit for Eye Health as High-Impact Partner | 1.461 | EQS Group (EN) | Santen Pharmaceutical Co., Ltd.
Santen Joins Inaugural Global Summit for Eye Health as High-Impact Partner 05-Aug-2026 / 10:30 CET/CEST
The issuer is solely responsible for the... ► Artikel lesen | |
| 12.05. | Santen Pharmaceutical Co. Q1 GAAP EPS of ¥104.99, revenue of ¥291.62B | 1 | Seeking Alpha | ||
| 12.05. | Santen Pharmaceutical Co., Ltd. Announces Increase In Full Year Income | 1 | RTTNews | ||
| 06.11.25 | Sydnexis, Inc.: Sydnexis Announces UK Approval of Ryjunea by Partner Santen to Slow Progression of Childhood Myopia | 647 | Business Wire | Sydnexis, Inc., (www.sydnexis.com), a biopharmaceutical company focused on pediatric progressive myopia (PPM), today noted its partner Santen's announcement that the UK Medicines and Healthcare products... ► Artikel lesen | |
| 05.11.25 | Santen Receives UK Approval for Ryjunea (low-dose atropine 0.1 mg/ml) to Slow Progression of Childhood Myopia | 896 | PR Newswire | First MHRA-approved low-dose atropine eye drop to slow the progression of myopia (short-sightedness) in children aged 3-14 years with a progression rate of 0.5 D or more per year and... ► Artikel lesen |
9 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVARTIS | 138,26 | -0,75 % | RBC stuft NOVARTIS AG auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die kanadische Bank RBC hat die Einstufung für Novartis vor Zahlen für das dritte Quartal auf "Sector Perform" mit einem Kursziel von 120 Franken belassen. Der Pharmakonzern... ► Artikel lesen | |
| MPH HEALTH CARE | 27,800 | -1,77 % | Original-Research: MPH Health Care AG (von First Berlin Equity Research GmbH): Kaufen | Original-Research: MPH Health Care AG - from First Berlin Equity Research GmbH
21.09.2026 / 13:15 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| COMPASS PATHWAYS | 10,300 | -0,96 % | Renditeschock trifft Biotech: Wie Compass Pathways und Definium Therapeutics um Kapital ringen - und wo Emyria steht | ||
| HIGH TIDE | 2,405 | +1,48 % | High Tide erwirbt etablierten Cannabis-Laden in Chestermere, Alberta | CALGARY, AB / 9. Oktober 2026 / IRW-Press / High Tide Inc. ("High Tide" oder das "Unternehmen") (Nasdaq: HITI) (TSXV: HITI) (FWB: 2LYA), das erfolgreiche, auf
den Einzelhandel fokussierte Unternehmen... ► Artikel lesen | |
| SHANGHAI FOSUN PHARMACEUTICAL | 1,851 | -0,62 % | Shanghai Fosun Pharmaceutical (Group) Co., Ltd.: Fosun Pharma Announces H-Share Repurchase Plan of Up to HK$ 1 Billion | SHANGHAI, Sept 7, 2026 - (ACN Newswire) - Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ('Fosun Pharma', stock code: 600196.SH; 02196.HK) today announced an H share repurchase plan, under which the... ► Artikel lesen | |
| SAVARA | 3,936 | -2,41 % | Savara Inc.: Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026 | -- Company to Host Industry Evening Mini-Symposium on aPAP with Renowned Key Opinion Leaders --Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases... ► Artikel lesen | |
| PROMINO NUTRITIONAL SCIENCES | 0,019 | 0,00 % | Promino Nutritional Sciences, Inc.: Promino Secures Social Commerce Distribution Agreement for US$5 Million Minimum Product Purchases | Social Commerce Brands to purchase a minimum US$1 million of Promino products in Q4 2026 and each quarter of 2027 while funding and operating designated direct-to-consumer and social commerce channelsBurlington... ► Artikel lesen | |
| EVOLUS | 6,500 | -1,54 % | Biotech Stocks At 52-Week Highs - RenovoRx +15%, Evolus, Crinetics Pharmaceuticals, Apogee Therapeutics | CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - The following biotech stocks reached a 52-week high on August 31, 2026, driven by achieving new regulatory milestones or an upcoming acquisition.RenovoRx... ► Artikel lesen | |
| ATYR PHARMA | 0,150 | -2,61 % | aTyr Pharma partners with Einstein on cancer research | ||
| MINDWALK | 1,060 | -0,93 % | MindWalk Holdings Corp. Announces Leadership Update | Commercial Priorities Unchanged; LensAI Remains in Contracted, Recurring Deployments with Life Sciences Customers
MindWalk Holdings Corp. ("MindWalk") (NASDAQ: HYFT), a Bio-Native AI company, today... ► Artikel lesen | |
| CIPHER PHARMACEUTICALS | 8,350 | 0,00 % | Cipher Pharmaceuticals Announces the Appointment of Rajiv De Silva to its Board of Directors | ||
| STEVANATO GROUP | 17,100 | 0,00 % | Stevanato Group S.p.A.: Stevanato Group to Report Third Quarter 2026 Financial Results on November 3, 2026 | Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced... ► Artikel lesen | |
| NANO HOLDINGS | 0,436 | -0,91 % | Forge Nano Holdings, Inc. - 8-K, Current Report | ||
| NIPPON KAYAKU | 11,400 | +0,88 % | Dividendenbekanntmachungen (29.09.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) 77 BANK LTD JP3352000008 52 JPY 0,2906 EUR ACADIAN TIMBER CORP CA0042721005 0,29 CAD 0,1799 EUR ACOM CO LTD JP3108600002 11 JPY 0... ► Artikel lesen | |
| TEVA PHARMACEUTICAL INDUSTRIES | 40,180 | -0,04 % | Teva/Sanofi: Duvakitug Maintains Meaningful Efficacy Improvements In Long-term Extension Study | PETAH TIKVA (dpa-AFX) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries (TEVA), and Sanofi announced new positive data from the RELIEVE UCCD phase 2b long-term extension... ► Artikel lesen |
Das Unternehmen SANTEN PHARMACEUTICAL CO LTD ADR kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 9,550 Euro. Aus der Ausschüttung der letzten 12 Monate von insgesamt 0,00 Euro errechnet sich eine Dividendendrendite von 0,00 %.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SANTEN PHARMACEUTICAL CO LTD ADR finden Sie auf Wallstreet Online.